Contineum Therapeutics, Inc. Share Price
Equities
CTNM
US21217B1008
Biotechnology & Medical Research
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
14.7 USD | -6.73% | -6.43% | 0.00% |
04-30 | Morgan Stanley Starts Contineum Therapeutics With Overweight Rating | MT |
04-30 | Stifel Starts Contineum Therapeutics With Buy Rating, $29 Price Target | MT |
Sales 2024 * | - | Sales 2025 * | 15M 1.18B | Capitalization | 405M 31.77B |
---|---|---|---|---|---|
Net income 2024 * | - | Net income 2025 * | - | EV / Sales 2024 * | - |
Net cash position 2024 * | 204M 15.96B | Net cash position 2025 * | 59.74M 4.68B | EV / Sales 2025 * | 23 x |
P/E ratio 2024 * |
-
| P/E ratio 2025 * |
-
| Employees | 31 |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 65.58% |
1 day | -6.73% | ||
1 week | -6.43% | ||
Current month | -5.77% | ||
1 month | -6.49% |
Date | Price | Change | Volume |
---|---|---|---|
28/05/24 | 14.7 | -6.73% | 25,099 |
24/05/24 | 15.76 | -2.17% | 29,292 |
23/05/24 | 16.11 | +1.58% | 118,222 |
22/05/24 | 15.86 | -0.88% | 25,253 |
21/05/24 | 16 | +1.85% | 25,345 |
Delayed Quote Nasdaq, May 28, 2024 at 09:00 pm
More quotesQuarterly revenue - Rate of surprise
1st Jan change | Capi. | |
---|---|---|
0.00% | 405M | |
+54.05% | 63.85B | |
-2.02% | 41.83B | |
+40.01% | 40.47B | |
-10.22% | 27.17B | |
+13.42% | 26.52B | |
-21.60% | 18.69B | |
+2.89% | 12.73B | |
+22.40% | 12.11B | |
+27.49% | 12.07B |
- Stock Market
- Equities
- CTNM Stock